Amgen reported strong Q1 growth with revenues up 15% and adjusted EPS increasing by 19%. However, concerns surrounding Aranesp due to label changes and potential downward revision of 2007 guidance introduce uncertainty. The balanced outlook suggests a neutral short-term impact.

[0]